Technical Analysis for PROK - ProKidney Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| C | 2.12 | -21.96% | -0.60 |
PROK closed unchanged on Thursday, April 25, 2024, on 63 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 3
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -21.96% | |
| NR7 | Range Contraction | -21.96% | |
| NR7-2 | Range Contraction | -21.96% | |
| Wide Bands | Range Expansion | -21.96% | |
| Gapped Down | Weakness | -21.96% | |
| Calm After Storm | Range Contraction | -21.96% | |
| NR7 | Range Contraction | -21.96% | |
| NR7-2 | Range Contraction | -21.96% | |
| Inside Day | Range Contraction | -21.96% | |
| Wide Bands | Range Expansion | -21.96% |
| Alert | Time |
|---|---|
| Down 1 ATR | about 4 hours ago |
| Outside Day | about 5 hours ago |
| Down 5% | about 5 hours ago |
| Fell Below Previous Day's Low | about 5 hours ago |
| Fell Below 10 DMA | about 5 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/03/2024
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Health Sciences Pharmacy Cell Therapy FDA Kidney Disease Regenerative Medicine Breakthrough Therapy Chronic Kidney Disease Regenerative Medicine Advanced Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.51 |
| 52 Week Low | 1.12 |
| Average Volume | 787,679 |
| 200-Day Moving Average | 3.99 |
| 50-Day Moving Average | 1.70 |
| 20-Day Moving Average | 1.98 |
| 10-Day Moving Average | 2.45 |
| Average True Range | 0.34 |
| RSI (14) | 64.54 |
| ADX | 30.71 |
| +DI | 32.15 |
| -DI | 14.05 |
| Chandelier Exit (Long, 3 ATRs) | 2.34 |
| Chandelier Exit (Short, 3 ATRs) | 2.44 |
| Upper Bollinger Bands | 3.05 |
| Lower Bollinger Band | 0.92 |
| Percent B (%b) | 0.84 |
| BandWidth | 106.93 |
| MACD Line | 0.31 |
| MACD Signal Line | 0.22 |
| MACD Histogram | 0.0823 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.10 | ||||
| Resistance 3 (R3) | 3.06 | 2.90 | 3.04 | ||
| Resistance 2 (R2) | 2.90 | 2.80 | 2.92 | 3.01 | |
| Resistance 1 (R1) | 2.80 | 2.74 | 2.85 | 2.84 | 2.99 |
| Pivot Point | 2.64 | 2.64 | 2.66 | 2.66 | 2.64 |
| Support 1 (S1) | 2.54 | 2.54 | 2.59 | 2.58 | 2.43 |
| Support 2 (S2) | 2.38 | 2.48 | 2.40 | 2.41 | |
| Support 3 (S3) | 2.28 | 2.38 | 2.39 | ||
| Support 4 (S4) | 2.32 |
